摘要
细胞免疫在机体对恶性肿瘤的免疫应答中发挥重要作用。人细胞毒性T淋巴细胞相关抗原4(CTLA-4)通过抑制T细胞的激活,参与T细胞免疫耐受的诱导和维持。因此通过单克隆抗体阻断CTLA-4的作用,可刺激免疫细胞大量增殖,从而增强机体对肿瘤的免疫反应。本文主要综述了近年来CTLA-4单克隆抗体药物(Ipilimumab、Tremelimumab)的研究及其在临床的应用进展。
Cellular immune system plays a very important role in the body＇s immune response to malignant tumor. Cytotoxic T lymphocyte-associated antigen 4 （CTLA-4） involves in the induction and maintenance of T cell immune tolerance through inhibiting T cell activity, so the monoclonal antibody which blocks the CTLA-4 can stimulate the proliferation of immune cells, thereby enhances the body＇s immune response to the tumor. This paper mainly reviews the research progresses about CTLA4 monoclonal antibody drugs（ ipil- imumab and tremelimumab） in recent years and the clinical application progress of them.
出处
《临床肿瘤学杂志》
CAS
2013年第3期268-272,共5页
Chinese Clinical Oncology
